Clinical Trial

Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 21, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-04.
Trial Details
NCT Number NCT07338682
Lead Sponsor German University in Cairo
Conditions Cognition Disorders in Old Age, Cognitive and Behavioral Impairment
Enrollment 60 participants
Start Date 2025-08-27
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-21